锕锕锕锕锕锕～再深点+在线观看,痛痛痛痛痛痛疼疼色板推特,天天碰天天爱天天摸,成人18毛片女人

您好，歡迎來到上海士研管理咨詢有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專家智庫服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專家智庫服務(wù)：
    中國領(lǐng)先的行業(yè)專家知識(shí)信息服務(wù)供應(yīng)商，為需要專業(yè)洞見的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬余名專家顧問遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶提供一站式整合營(yíng)銷解決方案，助力企業(yè)線上線下獲客與品牌筑造。我們深信專業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
嘉賓信息
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 聯(lián)合創(chuàng)始人&首席執(zhí)行官
所屬公司： 輝大（上海）生物科技有限公司
個(gè)人簡(jiǎn)介：
姚璇博士為輝大基因創(chuàng)始人&首席執(zhí)行官，負(fù)責(zé)公司戰(zhàn)略布局、團(tuán)隊(duì)組建、項(xiàng)目推進(jìn)與體系建設(shè)。本科畢業(yè)于哈爾濱工業(yè)大學(xué)，并在中科院神經(jīng)科學(xué)研究所獲得神經(jīng)生物學(xué)博士學(xué)位，創(chuàng)立輝大前曾擔(dān)任中科院神經(jīng)科學(xué)研究所副高級(jí)研究員。期間專注于新型基因編輯技術(shù)、動(dòng)物模型建立及疾病治療應(yīng)用等多個(gè)領(lǐng)域的研究開發(fā)，在國際高水平期刊發(fā)表多項(xiàng)成果并申請(qǐng)多項(xiàng)發(fā)明專利。With a doctoral degree of Institute of Neuroscience, Chinese Academy of Sciences, Dr. Xuan Yao once served as Associate Senior Researcher at Institute of Neuroscience, Chinese Academy of Sciences, and has published many of his research achievements on Developmental Cell, Cell Research, Genome Biology and other international high-ranking journals.Before founding HuidaGene, Dr. Yao efficiently constructed knock-in mouse models as well as the world’s first knock-in macaques by optimizing gene editing techniques, innovated CRISPR technology to specifically remove entire chromosomes, opening new avenues for modeling and generating therapies for diseases such as Down Syndrome, and worked out an efficient method for somatic cell knockins and technical solutions for the treatment of monogenic diseases. He has an international frontier vision and gains insights into business transformation in terms of the application of new gene editing techniques in animal modeling and in disease treatment.
發(fā)布時(shí)間: 2023 - 06 - 26
點(diǎn)擊次數(shù): 0
所屬職位： 醫(yī)學(xué)副總裁
所屬公司： 榮昌生物
個(gè)人簡(jiǎn)介：
醫(yī)學(xué)博士。從事腫瘤領(lǐng)域臨床研究近二十年，曾任職于解放軍總醫(yī)院第五醫(yī)學(xué)中心消化腫瘤科副主任，副主任醫(yī)師，碩士生導(dǎo)師。參與全球多中心臨床研究，國內(nèi)創(chuàng)新藥的早期、晚期臨床研究三十余項(xiàng)。曾作為信達(dá)生物醫(yī)學(xué)科學(xué)與戰(zhàn)略腫瘤部負(fù)責(zé)人，領(lǐng)導(dǎo)了信迪利單抗、佩米替尼在消化腫瘤多個(gè)適應(yīng)癥的成功獲批，以及多個(gè)早期分子在中國和海外的臨床開發(fā)。在BMJ, Lancet Oncology, Science Advance，Clinical Cancer Research等知名期刊發(fā)表學(xué)術(shù)論文二十余篇。目前負(fù)責(zé)榮昌生物腫瘤產(chǎn)品的全球臨床開發(fā)。Senior Medical Oncologist with 20 years’ experiences in clinical studies, worked as deputy director of the GI Cancer Department of the Fifth Medical Center of PLA General Hospital. Successfully led the development of Sintilimab (anti-PD-1 antibody, Innovent) in GI cancer, got BLA approval for 1L HCC, 1L ESCC and 1L GC, Pemigetinib approval in greater China as global first FGFR inhibitor. Led early-stage and late-stage development of more than 20 oncology assets covering mAb, BsAb, small molecule and ADC. Published more than 20 peer-reviewed papers in BMJ, Lancet Oncology, Science Advance, Clinical Cancer Research, etc. Responsible for the global development strategy and implementation of Remegen oncology pipeline.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 首席商務(wù)官
所屬公司： 復(fù)星凱特生物科技有限公司
個(gè)人簡(jiǎn)介：
負(fù)責(zé)公司各項(xiàng)外部合作及復(fù)星凱特在中國的首款CAR-T的商業(yè)化開發(fā)，包括銷售、商務(wù)運(yùn)營(yíng)、市場(chǎng)、BD、和準(zhǔn)入。曾任上海復(fù)星醫(yī)藥集團(tuán)戰(zhàn)略部總監(jiān)，參與包括復(fù)星凱特合資建立、復(fù)星領(lǐng)智在內(nèi)的各項(xiàng)集團(tuán)內(nèi)重大投資合作項(xiàng)目。2008至2015年期間于上海交通大學(xué)上海免疫學(xué)研究從事腫瘤免疫及自身免疫病研究。He’s the Chief Commerical Officer of Fosun Kite Biotechnology Co., Ltd. In charge of Fosun Kite 's various external cooperation and the commercial development of the company's first CAR-T in China, including sales, commercial operations, marketing, access and BD.He used to be the director of the strategy department of Fosun Pharma, and participated in various major investment cooperation projects within the group, including the establishment of Fosun Kite joint venture and Fosun Lead.From 2008 to 2015, he was engaged in tumor immunity and autoimmune disease research at Shanghai Institute of Immunology, Shanghai Jiao Tong University.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 創(chuàng)始人、董事長(zhǎng)兼首席執(zhí)行官
所屬公司： 星奕昂
個(gè)人簡(jiǎn)介：
星奕昂創(chuàng)始人、董事長(zhǎng)兼首席執(zhí)行官王立群博士：中國科學(xué)技術(shù)大學(xué)細(xì)胞生物學(xué)學(xué)士、美國馬里蘭大學(xué)巴爾的摩分校分子生物學(xué)博士以及辛辛那提薩維爾大學(xué)工商碩士，美國國立健康研究院(NIH)博士后。王立群博士在美國和中國的生物制藥領(lǐng)域擁有豐富的專業(yè)技術(shù)和研發(fā)管理經(jīng)驗(yàn)。在成立星奕昂之前，曾任復(fù)星醫(yī)藥副總、首席技術(shù)官和美國凱特合資公司復(fù)星凱特的總裁。用不到三年時(shí)間帶領(lǐng)復(fù)星凱特完成了奕凱達(dá)的技術(shù)落地，注冊(cè)臨床和生產(chǎn)，成為獲中國藥監(jiān)局批準(zhǔn)上市的首個(gè)CAR-T產(chǎn)品。王立群博士曾在美國寶潔、百時(shí)美施貴寶、阿斯利康以及葛蘭素史克中國研發(fā)中心的重要管理崗位上任職近20年，參與和主導(dǎo)了多個(gè)新藥的研發(fā)及轉(zhuǎn)化工作。他在西比曼生物科技擔(dān)任首席運(yùn)營(yíng)官期間，全面管理公司運(yùn)營(yíng)、細(xì)胞治療產(chǎn)品的生產(chǎn)、藥理和臨床研究，并兼任干細(xì)胞事業(yè)部總經(jīng)理。Richard Liqun Wang Ph. D., MBA.? Founder, Chairman and CEO， Neukio Biotherapeutics? VP & CTO, Fosun Pharma? Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years? COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies? Head of Operations, GSK R&D Center in China? Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China? Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA? Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USARichard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業(yè)云服務(wù)